Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.
Eli Lilly’s latest TV ad, unveiled during the Grammys on Sunday night, highlights the importance of early diagnosis for ...
So far in 2025, the year’s biggest cultural events have served as launchpads for several of the industry's latest cancer ...
Cramer has been a fan of LLY for a while now and recently reiterated holding on to the stock. “Okay, the problem with Eli ...
Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...
Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...
Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback